Musi wa25 Kubvumbi, 2025, InnoCare Pharma yakazivisa kuti chizvarwa chayo chitsva chepan-TRK inhibitor zurletrectinib (ICP-723) chakapihwa mukana wekutarisa neCenter for Drug Evaluation (CDE) yeChina National Medical Products Administration (NMPA), iyo yakabvuma New Drug Application (NDA) yezurletrectinib yekurapa varwere vane bundu rakasimba rine NTRK gene fusions munguva pfupi yapfuura. Kuongorora kwekutanga ndeimwe yemitemo yakakosha yakaunzwa neCDE yekukurumidzisa kubvumidzwa kwemishonga.
Muongororo yekunyoresa varwere vane tumors dzakasimba dzeNTRK fusion-positive, zurletrectinib yakaratidza kushanda zvakanaka uye ine hunhu hwakanaka hwekuchengetedza.
Dr. Jasmine Cui, mumwe wevakatanga mushonga uyu, sachigaro uye CEO weInnoCare, vakati, "Tinofara kuti zurletrectinib yapihwa mukana wekutarisa mushonga uyu. Zurletrectinib yakaratidza kushanda zvakanaka uye kuchengetedzeka kwakanaka. Tinotarisira kuti ichapa nzira dziri nani dzekurapa varwere vanokodzera vane bundu rakasimba kare."
Zurletrectinib mushonga unodzivirira chirwere chepan-TRK wakagadzirwa neInnoCare. British Journal of Cancer, chikamu chemagazini yesainzi inotungamira Nature, yakaburitsa bepa rine musoro unoti "Zurletrectinib mushonga unodzivirira chirwere cheTRK wechizvarwa chinotevera une simba guru mumusoro kurwisa tumors dzeNTRK dzine fusion-positive dzine resistance chaiyo kune agents dzechizvarwa chekutanga".
Pepa iri rakaratidza kuti zurletrectinib yakaratidza simba guru pakurwisa TRKA, TRKB, uye TRKC WT kinases, pamwe nekuchinja kwe TRKA G595R uye TRKA G667C. Zurletrectinib yaishanda zvakanyanya kupfuura mamwe ma TRK inhibitors akatenderwa neFDA kana akaedzwa nekiriniki (larotrectinib) uye TRK inhibitors echizvarwa chinotevera (selitrectinib uye repotrectinib) achirwisa ma TRK inhibitors akawanda. Saizvozvowo, zurletrectinib (1 mg/kg BID) yakadzivirira kukura kwegomarara mu xenograft models dzinobva kumasero eNTRK fusion-positive pachiyero chakaderera ka30 kana zvichienzaniswa neselitrectinib.
Pepa iri rakaratidzawo kuti, muongororo yemishonga yepakati petsinga (CNS) mumakonzo eSD, zurletrectinib yakaratidza kugona kwakawedzerwa kupinda muropa-uropi, zvichisvika muuropi zvinobudirira kupfuura selitrectinib nerepotrectinib. Kuwedzera kwekupinda muuropi kweZurletrectinib kwakashandurwawo kuita basa rekudzivirira bundu. Mumuenzaniso we glioma xenograft yembeva ye orthotopic ine TRKA G598R/G670A resistance mutation, zurletrectinib (15 mg/kg) yakavandudza zvakanyanya kupona kwembeva dzine orthotopic NTRK fusion-positive, TRK-mutant gliomas (median survival = 41.5, 66.5, uye mazuva 104 e selitrectinib, repotrectinib, uye zurletrectinib zvichiteerana; P < 0.05), zvichiratidza kushanda zvakanaka zvichienzaniswa ne repotrectinib (15 mg/kg) uye selitrectinib (30 mg/kg) (P=0.0384 na 0.0022, zvichiteerana), ine hunhu hwakanaka hwekuchengetedza.
Majini eNTRK fusion anowanikwa mumhando dzakasiyana dzemabundu evakuru neevana. Mune mamwe mabundu asingawanzoitiki, akadai sesavary gland carcinoma, secretory breast cancer, uye infantile fibrosarcoma, kuwanda kweNTRK gene fusion kunodarika 90%. Zvinofungidzirwa kuti kune nyaya itsva dzinosvika 6,500 dzemabundu eNTRK fusion-positive solid tumors dzinoonekwa muChina gore rega rega. Kune zvinodiwa zvekiriniki zvisina kuzadzikiswa munzvimbo iyi nekuda kwekushaikwa kwenzira dzekurapa dzinoshanda.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Email：myimmnet@163.com
Nguva yekutumira: Chivabvu-07-2025